About Haemonetics Corporation
https://www.haemonetics.comHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital.
CEO
Christopher A. Simon
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-12-03 | Forward | 2:1 |
| 1993-01-11 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 190
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
BTIG
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
Baird
Outperform
Barrington Research
Outperform
Raymond James
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:6.02M
Value:$455.95M
BLACKROCK INC.
Shares:5.96M
Value:$451.28M
VANGUARD GROUP INC
Shares:4.83M
Value:$366.13M
Summary
Showing Top 3 of 414
About Haemonetics Corporation
https://www.haemonetics.comHaemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2026 | $327.31M ▲ | $136.25M ▼ | $38.68M ▲ | 11.82% ▲ | $0.81 ▲ | $86.75M ▼ |
| Q1-2026 | $321.39M ▼ | $137.99M ▲ | $34.03M ▼ | 10.59% ▼ | $0.71 ▼ | $93.7M ▼ |
| Q4-2025 | $330.6M ▼ | $121.72M ▼ | $57.98M ▲ | 17.54% ▲ | $1.17 ▲ | $99.54M ▲ |
| Q3-2025 | $348.54M ▲ | $140.89M ▲ | $37.49M ▲ | 10.76% ▲ | $0.75 ▲ | $95.14M ▲ |
| Q2-2025 | $345.51M | $139.5M | $33.83M | 9.79% | $0.66 | $88.98M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2026 | $296.43M ▲ | $2.44B ▼ | $1.59B ▲ | $849.17M ▼ |
| Q1-2026 | $292.9M ▼ | $2.46B ▲ | $1.58B ▼ | $882.3M ▲ |
| Q4-2025 | $306.76M ▼ | $2.45B ▼ | $1.63B ▲ | $820.84M ▼ |
| Q3-2025 | $320.85M ▲ | $2.53B ▲ | $1.62B ▼ | $906.86M ▲ |
| Q2-2025 | $299.28M | $2.53B | $1.65B | $878.85M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2026 | $38.68M ▲ | $111.32M ▲ | $-30.47M ▲ | $-76.55M ▼ | $3.53M ▲ | $106.31M ▲ |
| Q1-2026 | $34.03M ▼ | $17.39M ▼ | $-33M ▼ | $-2.44M ▲ | $-13.87M ▲ | $13.64M ▼ |
| Q4-2025 | $57.98M ▲ | $116.56M ▲ | $18.04M ▲ | $-151.45M ▼ | $-14.08M ▼ | $100.91M ▲ |
| Q3-2025 | $37.49M ▲ | $43.77M ▼ | $-17.37M ▲ | $1.38M ▲ | $21.56M ▲ | $35.22M ▼ |
| Q2-2025 | $33.83M | $48.82M | $-23.37M | $-74.8M | $-45.15M | $39.39M |
Revenue by Products
| Product | Q4-2025 | Q3-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|
 Apheresis Blood Center | $0 ▲ | $0 ▲ | $0 ▲ | $60.00M ▲ |
 Blood Center | $50.00M ▲ | $70.00M ▲ | $50.00M ▼ | $60.00M ▲ |
 Hemostasis Management Hospital | $0 ▲ | $0 ▲ | $0 ▲ | $90.00M ▲ |
 Hospital | $150.00M ▲ | $140.00M ▼ | $140.00M ▲ | $150.00M ▲ |
 Interventional Technologies Hospital | $0 ▲ | $0 ▲ | $0 ▲ | $60.00M ▲ |
 Plasma | $130.00M ▲ | $130.00M ▲ | $130.00M ▲ | $130.00M ▲ |
 Whole Blood Blood Center | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|
 Asia | $30.00M ▲ | $20.00M ▼ | $20.00M ▲ | $40.00M ▲ |
 Europe | $40.00M ▲ | $40.00M ▲ | $40.00M ▲ | $80.00M ▲ |
 JAPAN | $20.00M ▲ | $20.00M ▲ | $10.00M ▼ | $30.00M ▲ |
 Other Country or Region | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
 UNITED STATES | $260.00M ▲ | $250.00M ▼ | $240.00M ▼ | $480.00M ▲ |
CEO
Christopher A. Simon
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-12-03 | Forward | 2:1 |
| 1993-01-11 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 190
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
BTIG
Buy
JMP Securities
Market Outperform
Mizuho
Outperform
Baird
Outperform
Barrington Research
Outperform
Raymond James
Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:6.02M
Value:$455.95M
BLACKROCK INC.
Shares:5.96M
Value:$451.28M
VANGUARD GROUP INC
Shares:4.83M
Value:$366.13M
Summary
Showing Top 3 of 414